Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial
Yi‐Long Wu(Guangdong Academy of Medical Sciences), Tae Min Kim(Seoul National University), Xiuning Le(The University of Texas MD Anderson Cancer Center), Ernest Nadal(Institut d'Investigació Biomédica de Bellvitge), Egbert F. Smit(Dutch Cancer Society), Giovanna Finocchiaro(Istituti di Ricovero e Cura a Carattere Scientifico), Christopher Stroh(Universität Hamburg), Puey Ling Chia(Tan Tock Seng Hospital), Christophe Dooms(Chinese Academy of Medical Sciences & Peking Union Medical College), Aurora O’Brate(Scripps Research Institute), Karin Berghoff(Merck KGaA, Darmstadt (Germany)), Svenja Adrian, Martin Wermke(National Center for Tumor Diseases), Valentina Guarneri(Istituto Oncologico Veneto), Lye Mun Tho(Hospital Kuala Lumpur), Pei Jye Voon(University Health Network), Rainer Strotmann(Leipzig University), Dilafruz Juraeva(Merck KGaA, Darmstadt (Germany)), Marie Wislez(Inserm), Chong Kin Liam(University of Malaya), Julien Mazieres(Université Toulouse III - Paul Sabatier), Boris M. Pfeiffer(Merck KGaA, Darmstadt (Germany)), Daniel S.W. Tan(Chinese Academy of Medical Sciences & Peking Union Medical College), Masahiro Morise(Nagoya University), Kosalaram Goteti(Ono Pharmaceutical (United States)), Niki Karachaliou(Institut Català d'Oncologia), Barbara Ellers‐Lenz(Merck KGaA, Darmstadt (Germany)), Terufumi Kato(Taipei Veterans General Hospital), Jialei Wang(Huaian First People’s Hospital), Jin‐Ji Yang(Guangdong General Hospital), Qinghua Zhou(Sichuan University), Anh T. Le(University of Colorado Anschutz Medical Campus), Nguyen Viet Nhung(VNU University of Science), Hidetoshi Hayashi(Kindai University), Cheng Huang(Army Medical University), How Soon Hin(Hospital Tengku Ampuan Afzan), Jo Raskin(Inserm), Boon Khaw Lim(Sunway University), Filippo de Marinis(Carlo Forlanini Hospital)
Cited by 98
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k